Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile

被引：246

作者：

Schmidt, AW ^{[1
]}

Lebel, LA ^{[1
]}

Howard, HR ^{[1
]}

Zorn, SH ^{[1
]}

机构：

[1] Pfizer Inc, Global Res & Dev, Groton Labs, CNS Discovery, Groton, CT 06340 USA

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2001年 / 425卷 / 03期

关键词：

antipsychotic agent; ziprasidone; receptor binding; human;

D O I：

10.1016/S0014-2999(01)01188-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ziprasidone is a novel antipsychotic agent with a unique combination of pharmacological activities at human receptors. Ziprasidone has high affinity for human 5-HT receptors and for human dopamine D-2 receptors. Ziprasidone is a 5-HT1A receptor agonist and an antagonist at 5-HT2A, 5-HT2C and 5-HT1B/1D receptors. Additionally, ziprasidone inhibits neuronal uptake of 5-HT and norepinephrine comparable to the antidepressant imipramine. This unique pharmacological profile of ziprasidone may be related to its clinical effectiveness as a treatment for the positive, negative and affective symptoms of schizophrenia with a low propensity for extrapyramidal side effects, cognitive deficits and weight gain. (C) 2001 Published by Elsevier Science B.V.

引用

页码：197 / 201

页数：5

共 12 条

[1]

Allison DB, 1999, AM J PSYCHIAT, V156, P1686

[2]

ALTAR CA, 1986, BRAIN RES BULL, V16, P517

[3]

[Anonymous], 1997, Journal of Serotonin Research

[4]

Casey DE, 2001, J CLIN PSYCHIAT, V62, P4

[5] DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS [J].

CREESE, I ;

BURT, DR ;

SNYDER, SH .

SCIENCE, 1976, 192 (4238) :481-483

[6] Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial [J].

Daniel, DG ;

Zimbroff, DL ;

Potkin, SG ;

Reeves, KR ;

Harrigan, EP ;

Lakshminarayanan, M .

NEUROPSYCHOPHARMACOLOGY, 1999, 20 (05) :491-505

[7] Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors:: a [35S]GTPγS binding study [J].

Newman-Tancredi, A ;

Gavaudan, S ;

Conte, C ;

Chaput, C ;

Touzard, M ;

Verrièle, L ;

Audinot, V ;

Millan, MJ .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 355 (2-3) :245-256

[8] Binding of antipsychotic drugs to human brain receptors - Focus on newer generation compounds [J].

Richelson, E ;

Souder, T .

LIFE SCIENCES, 2000, 68 (01) :29-39

[9] 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex [J].

Rollema, H ;

Lu, Y ;

Schmidt, AW ;

Sprouse, JS ;

Zorn, SH .

BIOLOGICAL PSYCHIATRY, 2000, 48 (03) :229-237

[10]

SEEGER TF, 1995, J PHARMACOL EXP THER, V275, P101

← 1 2 →